

### Factors associated with time to recovery among COVID-19 patients in selected Zambian hospitals, 2020

Kelvin Mwangilwa<sup>1</sup>, John Simwanza<sup>1</sup>, Samson Shumba<sup>2</sup>, Angela Gama<sup>1</sup>, Musole Chipoya<sup>1</sup>, Patrick Sakubita<sup>1</sup>, Nelia Mulambya<sup>1</sup>, Chikama Mukwangole<sup>1</sup>, Davies Simwaba<sup>1</sup>, Mazyanga Liwewe<sup>1</sup>, Moses Mwale<sup>2</sup>, Nyambe Sinyange<sup>1</sup>, Anayawa Nyambe<sup>1</sup>, Nkomba Kayeyi<sup>1</sup>, Muzala Kapina<sup>1</sup>, Joseph Mumba Zulu<sup>3</sup>, Peter Chipimo<sup>1</sup>, Nathan Kapata<sup>1</sup>, Isaac Fwemba<sup>3</sup>, Victor Mukonka<sup>1,4</sup>, Paul Msanzya Zulu<sup>11</sup>

<sup>1</sup>Zambia National Public Health Institute, 13 Reedbuck Road, Kabulonga, Lusaka, Zambia, <sup>2</sup>World Health Organization, P.O Box 32346, Lusaka, Zambia, <sup>3</sup>University of Zambia, School of Public Health, P.O. Box 5010, Ridgeway Campus, Lusaka, Zambia, <sup>4</sup>Levy Mwanawasa Medical University, P.O Box 33991, Lusaka, Zambia

#### ABSTRACT

Background: It is important to understand the time and factors associated with recovery to help improve response to the COVID-19 healthcare-related challenges and also to enhance information management. As a result, proof of the length of time it takes to recover from COVID-19 is required to develop effective treatment and prevention approaches. This study estimated the duration to recovery and related parameters of COVID-19-infected patients in Zambia for cases diagnosed between March 18 and June 26, 2020. Methods: The retrospective study examined 705 patients admitted to the fourteen COVID-19 isolation hospitals across Zambia. All COVID-19 tests used the RT-PCR of nasopharyngeal swabs. Recovery is operationally defined as a patient who presented a negative COVID-19 test on day 14 and was considered to have recovered. The Akaike Information Criteria (AIC) and Bayesian information criteria (BIC) were used to fit parametric models and pick the best predictive model. **Results:** Median time to recovery in the quarantine facilities was found to be 12 days (IQR 10-17). Out of 705 patients, 535 (75.9%) recovered within the median days of 14 days while 170 (24.1%) did not recover within the 14 days. In the adjusted model, a year increase in age of patients delayed time to recovery by 0.4% (ATR: 1.004, 95%CI; 1.002, 1.007; p=0.001). Similarly, patients admitted with shortness of breath had a delayed time to recovery by a factor of 11.4% (ATR: 1.114, 95%CI; 1.018, 1.221; p=0.019) compared to those with no shortness of breath. Conclusion: Age and shortness of breath at admission were associated with longer hospital stay among COVID-19 patients. These factors should be considered by program managers while making plans and policy recommendations for improved service delivery.

**KEYWORDS:** Corona Virus, Survival Analysis, Parametric Model, Log-Logistic Regression Model

#### \*CORRESPONDING AUTHOR

Kelvin Mwangilwa, Zambia National Public Health Institute, 13 Reedbuck Road, Kabulonga, Lusaka, Zambia

kelvinpetersj@gmail.com

**RECEIVED** 21/03/2022

ACCEPTED 06/02/2024

**PUBLISHED** 07/02/2024

LINK

www.afenet-journal.net/content/article/7/4/full/

© Kelvin Mwangilwa et al. Journal of Interventional Epidemiology and Public Health (ISSN: 2664-2824). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

CITATION

Kelvin Mwangilwa et al. Factors associated with time to recovery among COVID-19 patients in selected Zambian hospitals, 2020. J Interval Epidemiol Public Health. 2024 Feb; 7(1):4 DOI:

https://www.doi.org/10.37432/jieph.2024.7.1.95



#### Introduction

The COVID-19 disease global mortality rate is approximately 3.4 per 100,000 population, making it higher than that caused by most influenza virus strains [1]. Adult patients with underlying health conditions have been reported to be more susceptible to death from COVID-19 [2]. This risk of dying from COVID-19 increases further in the presence of one or more comorbidities [3].

There have been a few studies undertaken in Africa where the pandemic appears to be distinct from that of other continents in terms of virus propagation speed and mortality toll [4]. Case fatality rates have been 3.9 per cent worldwide, 7.1 per cent in Europe, 4.0 per cent in North America, 3.5 per cent in South America, and 2.1 per cent in Africa, with the most affected regions being South America, North America, and Europe [5]. Despite being the world's second most populous continent, with an estimated 17.2 per cent of the world's population, Africa accounts for only 5 per cent of total cases and 3 per cent of overall mortality as of August 1, 2020, when compared to other continents [4,6,7]. However, this could be due to underreporting [8], weak health systems coupled with high levels of poverty and inequalities in many of the countries [9].

On March 18, 2020, Zambia recorded its first COVID-19 case and by 21st May 2020, there were a total of 668 cases reported with 509 active cases, 152 (22.75%) recoveries and 7 (1.05%) deaths [10]. There is limited data on treatment outcomes of COVID-19 patients in Zambia, particularly on factors that determine recovery and discharge from hospitals or treatment centres [11]. Patients with COVID-19 in Zambia are managed from various hospitals and isolation facilities across the country. A study done in Ethiopia [3] on COVID-19 patients, determined the time from infection to negative conversion or recovery. Estimating the duration to recovery and the variables that influence recovery can aid in the formulation of preventative measures and the optimization of treatment. [3]. This study therefore assessed factors that determine time to recovery, from the time patients are admitted into care to the time they are discharged, at fourteen hospital isolation facilities in Zambia.

#### Methods

#### Study Design and Setting

This was a national hospital-based retrospective cohort study among COVID-19-positive patients admitted to 14 hospitals. The was considered to be the period between the initial positive test and the negative test at discharge. The observational period was 14 days; that is if a patient did not have a negative COVID-19 test on day 14 were considered to have not recovered and if they had a negative COVID-19 test on day 14 were considered to have recovered. The recovery time was arrived at using the Standard Operating Procedure (SOP) for the management of patients COVID-19 patients [12,13,14]. The study period was from 18<sup>th</sup> March to 26<sup>st</sup> May 2020 from the time the patients were admitted into care at the fourteen isolation facilities (Levy Mwanawasa Hospital, University Teaching Hospital, Chinsala general hospital, Nakonde district hospital, Kabwe Mine Hospital, Livingstone Central Hospital, Chipata Central Hospital, Lewanika general hospital, Mansa General Hospital, Masaiti Hospital, Ndola teaching hospital, Solwezi general, Lumwana district hospital and Kasama general hospital), to the time they recover.

### Study Population and Data Source

All COVID-19-positive patients registered on the Health Management Information System (HMIS) registration book and had full information about the severity of their disease and other sociodemographic characteristics were included. They included a total of 747 patients and about 7(0.9%) with incomplete clinical and demographic data were excluded. The data was obtained from Zambia National Public Health Institute, the institute responsible for disseminating COVID-19 updates for the country.

Patients admitted at health facilities during the study period had their nasopharyngeal swabs tested with the Real-Time Polymerase Chain Reaction (RT-PCR) according to Zambia National COVID-19 guidelines which are in line with World Health Organisation recommendations [15]. Standard treatment for all patients in all the facilities was in line with the COVID-19 treatment protocol by the Ministry of Health [12]. Hospital records of patients were reviewed, and data was captured using a Microsoft Excel spreadsheet showing the date when patients were diagnosed, the date when the patient started treatment and when the patient was discharged. The primary dependent variable was time to recovery from COVID-19 whereas the explanatory variables were social demographic variables (age, gender), symptoms (fever, cough, sore throat, dyspnoea, headache, chest pain, nausea, vomiting), and co-morbidity (tuberculosis, HIV).

### **Statistical Analysis**

The time to recovery was defined as the period between when patients were diagnosed positive for COVID-19 and when they were diagnosed negative by RT-PCR by two consecutive tests and were free of symptoms after admission to the hospital. The event was disease recovery, and patients who developed an event, died, or were transferred out of the study were censored.

The research population was described using descriptive statistics such as means, medians, interquartile ranges, percentages, frequencies, and standard deviations. Standard deviation (SD) was used to describe continuous variables for normally distributed variables. The Kaplan-Meier (KM) method was used to estimate recovery time from COVID-19, and the Log-rank test was utilized to compare survival times among categories of categorical factors. Before fitting the survival model, proportional hazard assumptions (PHA) were verified. To explore the relationships between continuous variables and the outcome, a Wilcoxon rank-sum test was used [16]. The study fitted multiple parametric models after PHA was not met for the best-fit model for the data in adjusted multivariable analysis. The models were fitted using Stata/MP version 14.2 (Stata Corporation, Texas, TX, USA), were Exponential, Weibull, Gompertz, Log-Logistic, Log-Normal, and Generalized Gamma and this has been reported elsewhere [17], Bayesian information criterion (BIC) were utilized to fit the best model. BIC is a criterion for model selection among a finite set of models [18]. Finally, the model with a lower number implies that the proposed model does well in fitting the data. The best-fitting survival model for the data was the loglogistic regression model. The accelerated failure time (AFT) family includes the Log-logistic distribution, which is useful for modelling nonmonotone hazard rates [16,17]. The assumption underpinning testing many models was that the probability of recovery was not well understood, and therefore picking a model that fits well helps in understanding the recovery process and the factors that increase or decrease recovery among COVID-19 patients [11,19].

#### **Operational Definition**

**Event:** In this study period, refers to the recovery of COVID-19-positive patient

**Length of stay:** refers to the period, measured in days, between the date of the admission and the patient's discharge from the treatment facility [<u>3</u>].

**Censored:** refers to patients who did not have a negative outcome, who have died, who have been lost to follow-up, and who have only had homebased care [20].

Time to recovery is determined by calculating the difference (in days) between the commencement of therapy and recovery. It represents the number of days from patient admission to recovery from COVID-19 [20].

**Co-morbidities:** refers to people with COVID-19 who have health problems such as TB and HIV, before, during, or after being admitted to treatment centers [20].

#### Ethical considerations

The information was gathered from the Zambia National Public Health Institute (ZNPHI), which is part of the Zambian Ministry of Health and permission was granted by the institute. ZNPHI monitors and keeps data from all patients in all health facilities and publishes country situational reports which provide statistics on the evolution of COVID-19 in Zambia. ZNPHI as a statutory institution on its own, granted permission to access, analyse and publish information from its database. No primary data was collected for this study and any information that can be used to identify individuals was removed. Permission was obtained to use the secondary data from the Zambia National Public Health Institute for this research, which is the custodian of the COVID-19 data in Zambia.

### Clinical and demographic characteristics

At the end of the follow-up, 705 (95.3%) of the patients recovered from COVID-19, and 35 (4.7%) were censored. Among those censored instances, 10 (28.6%) were released by isolated home-based care following clinical improvement, 6 (17.1%) were lost to follow-up from the treatment center, and 19 (54.3%) passed away while receiving treatment. Of the 705 patients quarantined, 169 (24.0%) were females and 536 (76.0%) were males. At the time of diagnosis, the median age was 39 years (IQR 3-77). There were 535 (75.9%) recoveries within 14 days and 170 (24.1%) did not recover within fourteen days.

The median recovery time was 12 days (IQR 10-17) and the total person time at risk was 9078 days. Assuming the incident rate (i.e. hazard function) is constant; the incident rate of recovery was estimated at 0.059 per day (5.9%) or 59 per 1000 persons per day. For seven days, recovery rate was 0.93 (0.93%) with a 95% confidence interval of 0.90, - 0.94, fourteen days the recovery was 0.50 (50.0.0%) and the 95% confidence interval of 0.46 - 0.54.

During the follow-up period, that is the period from the initial positive COVID-19 test to the negative test at discharge, 412 (72.9%) recovered. The median age of patients who recovered from COVID-19 was 36 years (IQR = 30, 45) compared to those who did not recover at 45 years (IQR = 35, 56). Age (p=0.001) Fever (p=0.036), sore throat (p=0.001), and shortness of breath (p=0.015) were all associated with recovery (<u>Table 1</u>).

COVID-19 patients who presented with shortness of breath at diagnosis had lower recovery probability and this was statistically significant with p-value= 0.015. Below four days after diagnosis, patients in both groups had an equal probability of recovery, while from four days to the fourteenth day, the recovery between the two groups were different and the fourteenth day and beyond the two groups were different (Figure 1). COVID-19 patients who presented with sore throats at diagnosis had lower recovery probability and this was statistically significant (p-value= 0.001). Between days five and ten patients who had sore throats had lower probabilities of recovery, while from about the eleventh day, there was no difference in the recovery but after the thirteenth day probability of recovery seemed to have swapped between the two groups going forward (<u>Figure 2</u>).

Patients in the COVID-19 study who had a fever at the time of diagnosis had a greater chance of recovery, which was statistically significant (pvalue=0.036). Below ten days after diagnosis, patients in both groups had an equal probability of recovery, while from day eleven and beyond recovery between the two groups was different (**Figure 3**).

### Best fit Model

The model with the lowest value of the BIC was Log-Logistic and fit the data quite well. This implies that the risk of patients follows a Log-logistic function implying that risk exhibits a non-monotonicity hazard function that is it starts to increase in the early stage of the disease and later decreases (Table 2).

An unadjusted model, not adjusting for confounders, a year increase in age of patients delayed time to recovery by 0.5% (Time Ratio: 1.005, 95%CI; 1.002, 1.007; p=0.001); shortness of breath delayed time to recovery for in patients diagnosed with COVID-19 by 13.5% (Time Ratio: 1.004, 95%CI; 1.041, 1.240; p=0.001).

Further analysis using an adjusted Log-Logistic model showed that a year increase in age of patients delayed time to recovery by a factor of 0.4% (Adjusted Time Ratio: 1.004, CI 95%; 1.002, 1.007; p=0.001) holding all other factors constant. Likewise controlling for all other variables, patients who had presented with shortness of breath compared to those without had delayed time to recovery by a factor of 11.4% (ATR: 1.114, CI 95%; 1.018, 1.221; p=0.019). All the other factors examined both the unadjusted and adjusted models failed to predict the time to recovery of COVID-19 patients (Table 3).

### Discussion

It is important to understand the time and factors associated with recovery to help health systems improve their response to COVID-19. Age and dyspnoea played a major influence in COVID-19 patients' delayed time to recovery, according to the results of the Log-Logistic model. Patients in the hospital were found to be discharged by 12 median days (IQR 10-17) after admission in this retrospective analysis. Comparable estimates have been reported in previous studies [21,22]. The relatively long time from onset of illness to hospital admission could be a factor in the longer onset to recovery time; the median time from onset of illness to hospital admission was 15 days (IQR 7.0-30.0), while the median time from onset of illness to hospital discharge was 30.0 days (IQR 21.5-43.0).

An increase in the age of COVID-19 patients significantly delayed the time to recover from COVID-19. Earlier reports noted that being of older age prolonged the time to recovery from COVID-19 [23]. Another study concluded that longer hospital stays were linked to inpatients aged 45 years and above [24].

The study also found that COVID-19 patients who presented with shortness of breath at diagnosis had delayed time to recovery. This could be due to the worsening severity of the cases with reported shortness of breath. The relationship between shortness of breath and recovery from COVID-19 has earlier been reported [24,25]. This study suggests that even among symptomatic individuals examined in outpatient settings, symptom relief and return to normal health could take weeks [26]. Oxygen levels dip as the viral load continues to increase causing more damage to the body's respiratory linings compromising functionality and breathlessness and low oxygen saturation can continue to occur, even after the virus diminishes from the body [27].

Major limitations were missing information on the patient's clinical records from the hospital where the patients were quarantined and hence limited observations in our study as a result; only patients with complete information were included. Another limitation was that the lack of commodities to do two tests at discharge.

#### Conclusion

The findings of the study show that older age patients were less likely to recover faster than younger patients. Therefore, patients of older age need more care, early detection and management can help to prevent the onset of serious illness of COVID-19. Also, patients who presented with dyspnoea need careful observation and interventions to avoid delay in recovery from COVID-19. To better respond to COVID-19-related difficulties and improve health information management, the health system must be strengthened. Modelling COVID-19 data was critical to better understand the elements that influence recovery time after COVID-19 infection by utilizing the best model that provided more accurate estimations.

#### What is known about this topic

- A notable percentage of persons with SARS-CoV-2 infection still had symptoms nearly two months after their diagnosis
- The log-logistic AFT model accurately described the recovery time of patients with COVID-19
- The median recovery time of patients with COVID-19 cases was long, and factors such as older age group, presence of fever, and comorbidity was an independent predictors of delayed recovery from COVID-19

#### What this study adds

- To better response to COVID-19-related difficulties and improve health information management, the health system must be strengthened
- Therefore, the patients with older age need more care, early detection and management can help to prevent the onset of serious illness of COVID-19
- Modelling COVID-19 data was critical in order to better understand the elements that influence recovery time especially in Africa set up after COVID-19 infection by utilizing the best model that provided more accurate estimations

#### **Competing interests**

There are no competing interests declared by the author(s). There is no sponsorship for this research. On request, the datasets used in or analyzed during the current work may be obtained from the corresponding author.

Authors' contributions

#### Conceptualization of the article: KM

Data Curation: KM, JS, MM, PS, NM, CM, MC.

**Investigations and Methodology:** KM, JS, MM, PJC, IF, RH, NS, AG, JMZ, MML, DS, PS, MC, NM, CM, SS

Data analysis and interpretation: KM, KM, PMZ, AN, JS, NS, JMZ, IF, DS, NK, MM, AG, KM, MML, PS, NM, CM, PMZ

Writing-original draft: KM KM, MC, PS, MM, NM, PJC, MML, NK, DS, VM, IF, NK, JMZ, AG, AN, NK, MML, PMZ, NS, KM, JMZ, DS, and SS read and approved the final document after reviewing it and providing written suggestions to improve the overall presentation of the results.

#### **Tables and figures**

Table 1Demographic and clinical characteristics of705COVID-19patientsisolatedatdifferenthospitalsinZambia.

<u>**Table 2**</u>: Comparison of the BIC between Parametric Models

<u>**Table 3**</u>: Crude and Adjusted Time Ratios of the COVID-19 patients using the Log Logistic Model.

Figure 1: Estimates of the recovery time in days of COVID-19 patients

Figure 2: Estimates of the recovery time in days of COVID-19 patients

**Figure 3**: Estimates of the recovery time in days of COVID-19 patients

- an CH, Faraji F, Prajapati DP, Ostrander BT, DeConde AS.<u>Self-reported olfactory</u> <u>loss associates with outpatient clinical</u> <u>course in COVID-19</u>. Int Forum Allergy Rhinol [Internet]. 2020 Apr 24 [cited 2024 Jan 18];10(7):821-3. <u>https://doi.org/10.1002/alr.22592 Pub</u> <u>Med | Google Scholar</u>
- Prompetchara E, Ketloy C, Palaga T.<u>Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic</u>. Asian Pac J Allergy Immunol [Internet]. 2020 Mar [cited 2024 Jan 18];38(1):1-9. <u>https://doi.org/10.12932/AP-200220-0772 PubMed | Google Scholar</u>
- 3. Abrahim SA, Tessema M, Defar A, Hussen A, Ejeta E, Demoz G, Tereda AB, Dillnessa E, Feleke A, Amare M, Nigatu F, Fufa Y, Refera H, Aklilu A, Kassa M, Kifle T, Whiting S, Tollera G, Abate E.Time to recovery and its predictors among adults hospitalized with COVID-19: Α prospective cohort study in Ethiopia. Lazzeri C, editor. PLoS ONE [Internet]. 2020 30 Dec [cited 2024 Jan 18];15(12):e0244269. https://doi.org/10.1 371/journal.pone.0244269 PubMed | Goo **Scholar** gle
- Bamgboye EL, Omiye JA, Afolaranmi OJ, Davids MR, Tannor EK, Wadee S, Niang A, Were A, Naicker S.<u>Covid-19 pandemic: is</u> <u>Africa different?</u> Journal of the National Medical Association [Internet]. 2020 Nov 3[cited 2024 Jan 18];113(3):324-35. <u>https://doi.org/10.1016/j.jnma.2020.</u> <u>10.001 PubMed</u> | <u>Google Scholar</u>
- Bernal HDM, Siqueira CE, Adami F, Santos EFDS. <u>Trends in case-fatality rates of</u> <u>COVID-19 in the World between 2019 -</u> <u>2020</u>. JHGD [Internet]. 2020 Oct 15 [cited 2024 Jan 18];30(3):344-54. <u>http://dx.doi.org/10.7322/jhgd.v30.1</u> <u>1063 PubMed</u> | <u>Google Scholar</u>

- 6. Bwire G, Ario AR, Eyu P, Ocom F, Wamala JF, Kusi KA, Ndeketa L, Jambo KC, Wanyenze RK, Talisuna AO.<u>The COVID-19 pandemic in the African continent</u>. BMC Med [Internet]. 2022 May 2 [cited 2024 Jan 18];20(1):167. <u>https://doi.org/10.1186/s1 2916-022-02367-4 PubMed</u> | <u>Google Scholar</u>
- 7. Teh JKL, Bradley DA, Chook JB, Lai KH, Ang WT, Teo KL, Peh SC.<u>Multivariate</u> visualization of the global COVID-19 pandemic: A comparison of 161 countries. Abbas F, editor. PLoS ONE [Internet]. 2021 May 28 [cited 2024 Jan 18];16(5):e0252273. <u>https://doi.org/10.13</u> 71/journal.pone.0252273 PubMed | Goog le Scholar
- 8. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard [Internet]. Geneva(Switzerland): World Health Organization; 2020 [cited 2024 Jan 18]. PubMed | Google Scholar
- 9. Shamasunder S, Holmes SM, Goronga T, Carrasco H, Katz E, Frankfurter R, Keshavjee S.<u>COVID-19 reveals weak</u> <u>health systems by design: Why we must remake global health in this historic</u> <u>moment</u>. Global Public Health [Internet]. 2020 Apr 30 [cited 2024 Jan 18];15(7):1083-9 <u>https://doi.org/10.1080/17441692.2020</u> <u>.1760915 PubMed</u> | <u>Google Scholar</u>

- 10. Mudenda S, Mukosha M, Mwila C, Saleem Z, Kalungia AC, Munkombwe D, Daka V, Witika BA, Kampamba M, Hikaambo CN, Sadiq MJ, Chileshe M, Kasanga M, Mufwambi W, Mfune RL, Matafwali SK, Masebe PO, Muungo LT, Bwalya AG, Kampamba RM, Zingani E, Banda DC, Sintema EJ, Gupta A, Abdulrahman NM, Hangoma JM, Phiri MN, Hang'andu D, Mudenda F, Mudenda F, Banda M, Kazonga E.Impact of the coronavirus disease on the mental health and physical activity of pharmacy students at the University of Zambia: a cross-sectional study. Int J Basic Clin Pharmacol [Internet]. 2021 Mar 22 [cited 2024 Jan 18];10(4):324-332. https://doi.org/18203/2319-2003.ijbcp20211010 PubMed | Google Scholar
- 11. Mollazehi M, Mollazehi M, Abdel-Salam ASG.<u>Modeling survival time to recovery</u> <u>from COVID-19: a case study on</u> <u>Singapore</u>. Version: 1. ResearchSquare [Preprint]. [posted 2020 Mar 23; revised 2020 Mar 30; cited 2024 Jan 31]. <u>https://doi.org/10.21203/rs.3.rs-</u> <u>18600/v1 PubMed</u> | <u>Google</u> Scholar
- 12. Zambia Ministry of Health.<u>Clinical</u> <u>Guidance for Management of Patients with</u> <u>Coronavirus Disease 2019 (COVID-</u> <u>19)</u> [Internet]. Lusaka (Zambia): Zambia Ministry of Health; 2020 Dec [cited 2024 Jan 18]. 91p. Download Microsoft Word - For Circulation\_14.01.21\_COVID-19 CM Guidelines\_Zambia-Second wave version.docx. <u>PubMed</u> | <u>Google Scholar</u>
- 13. Byambasuren O, Cardona M, Bell K, Clark J, McLaws ML, Glasziou P. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: Systematic review and meta-analysis. Official Journal of the Association of Medical Microbiology and Infectious Disease Canada [Internet]. 2020 Dec 31 [cited 2024 Jan 19];5(4):223-34. https://doi.org/10.3138/jammi-2020-0030 PubMed | Google **Scholar**

- 14. Chiotos K, Bassiri H, Behrens EM, Blatz AM, Chang J, Diorio C, Fitzgerald JC, Topjian A, John ARO. Multisystem inflammatory syndrome in children during the coronavirus 2019 pandemic: a case series. Journal of the Pediatric Infectious Diseases Society [Internet]. 2020 May 28 [cited] 2024 Jan 19];9(3):393-8. https://doi.org/10.1093/jpids/piaa069 PubMed | Google **Scholar**
- 15. World Health Organization. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: Interim Guidance [Internet]. Geneva (Switzerland): World Health Organization; 2020 Mar 19 [cited 2024 Jan 18]. 7 p. Download Microsoft Word - Lab guidance 2020-03-19e\_en\_2020.5.docx WHO/COVID-19/laboratory/2020.5. PubMed | Google Scholar
- 16. Mwangilwa K, Mwale M, Citonje S, Vinikool M, Musonda P.<u>Modelling survival</u> and factors associated with HIV-infected and -uninfected patients of prostate cancer at the University Teaching Hospital, Lusaka, Zambia. Cogent Public Health [Internet]. 2023 Jun 15 [cited 2024 Jan 19];10(1):2224514. <u>https://doi.org/10.108</u> 0/27707571.2023.2224514 PubMed | Goo gle Scholar
- 17. Khan SA, Khosa SK.<u>Generalized log-logistic proportional hazard model with applications in survival analysis</u>. J Stat Distrib App [Internet]. 2016 Nov 29 [cited 2024 Jan 19];3(1):16. <u>https://doi.org/10.1186/s404 88-016-0054-z PubMed | Google Scholar</u>
- 18. Vrieze SI.<u>Model selection and psychological theory: A discussion of the differences between the Akaike information criterion (Aic) and the Bayesian information criterion (Bic). Psychological Methods [Internet]. 2012 Jun [cited 2024 Jan 19];17(2):228-43. <u>https://doi.org/10.1037/a0027127 Pu bMed | Google Scholar</u></u>

- 19. Thiruvengadam G, Ramanujam R, Marappa L.Modeling the recovery time of patients with coronavirus disease 2019 using an accelerated failure time model. J Int Med Res [Internet]. 2021 Aug 31 [cited 2024 Jan 19];49(8):030006052110402. https://doi.or g/10.1177/03000605211040263 PubMed | Google Scholar
- 20. Kaso AW, Hareru HE, Kaso T, Agero G. <u>Time to recovery from Covid-19 and its</u> <u>associated factors among patients</u> <u>hospitalized to the treatment center in</u> <u>South Central Ethiopia</u>. Environmental Challenges [Internet]. 2021 Dec 16 [cited 2024 Jan 19];6:100428. <u>https://doi.org/10.1016/j.e</u> <u>nvc.2021.100428 PubMed</u> | <u>Google</u> <u>Scholar</u>
- 21. Rees EM, Nightingale ES, Jafari Y, Waterlow NR, Clifford S, B. Pearson CA, Group CW, Jombart T, Procter SR, Knight GM.<u>COVID-19 length of hospital stay: a</u> <u>systematic review and data synthesis</u>. BMC Med [Internet]. 2020 Sep 3 [cited 2024 Jan 19];18(1):270. <u>https://doi.org/10.1186/s1</u> <u>2916-020-01726-3 PubMed | Google</u> Scholar
- 22. Wu Y, Hou B, Liu J, Chen Y, Zhong P.<u>Risk factors associated with long-term hospitalization in patients with covid-19: a single-centered, retrospective study</u>. Front Med [Internet]. 2020 Jun 9 [cited 2024 Jan 19];7:315. <u>https://doi.org/10.3389/fmed. 2020.00315 PubMed | Google Scholar</u>
- 23. Tolossa T, Wakuma B, Seyoum Gebre D, Merdassa Atomssa E, Getachew M, Fetensa G, Ayala D, Turi E.<u>Time to recovery from</u> <u>COVID-19 and its predictors among</u> <u>patients admitted to treatment center of</u> <u>Wollega University Referral Hospital</u>

(Wurh), Western Ethiopia: Survival analysis of retrospective cohort study. Lazzeri C, editor. PLoS ONE [Internet]. 2021 Jun 10 [cited 2024 Jan 19];16(6):e0252389. https://doi.org/10.13 71/journal.pone.0252389 PubMed | Goog le Scholar

24. Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, Li F, Xu Q, Zhang Y, Xu S, Song Z, Zeng Y, Shen Y, Shi Y, Zhu T, Lu H. Clinical progression of patients with COVID-19 in Shanghai, China. Journal of Infection [Internet]. 2020 Mar 11 [cited 2024 Jan 19];80(5):e16. https://doi.org/10.1016/j.jinf.2020.03.

<u>004 PubMed | Google Scholar</u>


- 25. Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. <u>Management of postacute COVID-19 in primary care</u>. BMJ [Internet]. 2020 Aug 11 [cited 2024 Jan 19];370:m3026. <u>https://doi.org/10.1136/ bmj.m3026 PubMed</u> | <u>Google Scholar</u>
- 26. Tenforde MW.<u>Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a Multistate Health Care Systems Network United States, March-June 2020. MMWR Morb Mortal Wkly Rep [Internet]. 2020 Jul 31 [cited 2024 Jan 19];69(30):993-998. <u>http://dx.doi.org/10.15585/mmwr.mm6930e1 PubMed | Google Scholar</u>
  </u>
- 27. Biguenet A, Bouiller K, Marty-Quinternet S, Brunel A, Chirouze C, Lepiller Q.<u>SARS-CoV-2 respiratory viral loads and association with clinical and biological features</u>. Journal of Medical Virology [Internet]. 2020 Sep 5 [cited 2024 Jan 19];93(3):1761-

5. <u>https://doi.org/10.1002/jmv.26489 Pu</u> <u>bMed</u> | <u>Google Scholar</u>

Factors	Positive COVID-19 patients		P-value
	(Total sample= 564)		
	Recovered	<b>Not recovered</b> N= 170 (24.1%)	
	N= 535 (75.9%)		
Age years, median (IQR)	36 years (30.45)	45 years (35.56)	0.001 <sup>w</sup>
Gender			-
Female	137 (25.6%)	32 (18.8%)	
Male	398 (74.4%)	138 (81.20%)	0.071 <sup>c</sup>
Fever			1
No	423 (79.1%)	143 (84.1%)	
Yes	112 (20.9%)	27 (15.9%)	0.036 <sup>c</sup>
Cough			
No	307 (57.4%)	92 (54.1%)	
Yes	228 (42.6%)	78 (45.9%)	0.454 <sup>c</sup>
Sore throat			
No	383 (71.6%)	126 (74.1%)	
Yes	152 (28.4%)	44 (25.9%)	0.001 <sup>C</sup>
Dyspnoea			
No	417 (77.9%)	147 (86.5%)	
Yes	118 (22.1%)	23 (13.5%)	0.015 <sup>C</sup>
Headache	• • • • •		•
No	341 (63.7%)	100 (65.4%)	
Yes	60 (36.3%)	53 (34.6%)	0.819 <sup>c</sup>
Chest Pain			
No	374 (69.9%)	125 (74.7%)	
Yes	161 (30.1%)	45 (26.5%)	0.366 <sup>C</sup>
Nausea			•
No	400 (74.8%)	127 (74.7%)	
Yes	135 (25.2%)	43 (25.2%)	0.987 <sup>c</sup>
Vomiting		· · · · · ·	•
No	438 (81.9%)	144 (84.7%)	
Yes	97 (18.1%)	26 (15.3%)	0.396 <sup>c</sup>
Tuberculosis		- (	
No	366 (68.4%)	121 (71.2%)	
Yes	169 (31.6%)	49 (28.8%)	0.497 <sup>c</sup>
HIV			5.177
No	465 (86.9%)	154 (90.6%)	
Yes	70 (13.1%)	16 (9.4%)	0.202 <sup>c</sup>


Table 2: Comparison of the BIC between Parametric Models					
Model	Number of Parameters	BIC			
ExQonential	12	1646.709			
Weibull	13	1269.99			
	13	1480.346			
Log-Normal	13	1157.343			
Log-Logistic	13	1131.675			
Generalised Gamma	14	1159.769			

Factors	Crude	p-value	Adjusted	p-value
	Time Ratio (95% CI)		Time Ratio (95%CI)	
Age, years	1.005 (1.002, 1.007)	0.001	1.004 (1.002, 1.007)	0.001
Gender	•			
Female	Ref (1)		Ref (1)	
Male	0.993 (0.9167, 1.0757)	0.861	0.998 (0.924, 1.086)	0.969
Fever		-		
No	Ref (1)		Ref (1)	
Yes	1.062 (0.9714, 1.162)	0.187	1.029 (0.942, 1.125)	0.522
Cough	1			
No	Ref (1)		Ref (1)	
Yes	1.009 (0.940, 1.083)	0.899	0.993 (0.923, 2.366)	0.861
Sore throat				
No	Ref (1)		Ref (1)	
Yes	1.062 (0.981, 1.149)	0.138	1.058 (0.977, 1.178)	0.164
Dyspnoea		•		
No	Ref (1)		Ref (1)	
Yes	1.135 (1.041, 1.240,)	0.004	1.114 (1.018, 1.221)	0.019
Headache				•
No	Ref (1)	Ref	Ref (1)	
Yes	0.995 (0.925, 1.070)	0.899	0.982 (0.911, 1.058)	0.635
Chest pain				•
No	Ref (1)		Ref (1)	
Yes	1.060 (0.981, 1.145)	0. 139	1.051 (0.970, 1.138)	0.220
Vomiting		•		
No	Ref (1)		Ref (1)	
Yes	0.990 (0.904, 1.085)	0.832	0.960 (0.874, 1.473)	0.387
Tuberculosis	5 5			
No	Ref (1)		Ref (1)	
Yes	0.998 (0.926, 1.077)	0.961	0.996 (0.923, 2.529)	0.928
HIV	1		1	1
No	Ref (1)		Ref (1)	
Yes	1.057 (0.949, 1.175)	0.258	1.043 (0.933, 1.579)	0.457




# Figure 1: Estimates of the recovery time in days of COVID-19 patients

Figure 1: Estimates of the recovery time in days of COVID-19 patients



# Figure 2: Estimates of the recovery time in days of COVID-19 patients

Figure 2: Estimates of the recovery time in days of COVID-19 patients



# Figure 3: Estimates of the recovery time in days of COVID-19 patients

Figure 3: Estimates of the recovery time in days of COVID-19 patients